GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

The Cutaneous Oncology Program at the George Washington University (GW) Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.